Article Text

Download PDFPDF

80 Tumor-specific alternative splicing generates immunogenic spatially-conserved HLA-binding neoantigens detected through integrative transcriptomic and proteomic analyses
  1. Darwin Kwok,
  2. Takahide Nejo,
  3. Chibo Hong,
  4. Aidan Du,
  5. Maggie Colton,
  6. James Woo,
  7. Joseph Costello and
  8. Hideho Okada
  1. University of California San Francisco, San Francisco, CA, USA


Background While immunotherapy is profoundly efficacious in certain cancers, its success is limited in cancers with lower mutational burdens, such as gliomas.1 Therefore, investigating neoantigens beyond those from somatic mutations can expand the repertoire of immunotherapy targets. Recent studies detected alternative-splicing (AS) events in various cancer types that could potentially translate into tumor-specific proteins.2, 3 Our study investigates AS within glioma to identify novel MHC-I-presented neoantigens through an integrative transcriptomic and proteomic computational pipeline, complemented by an extensive spatiotemporal analysis of the AS candidates.

Methods Bulk RNA-seq of high tumor purity TCGA-GBM/LGG (n=429) were analyzed through a novel systematic pipeline, and tumor-specific splicing junctions (neojunctions) were identified in silico by cross-referencing with bulk RNA-seq of GTEx normal tissue (n=9,166). Two HLA-binding prediction algorithms were subsequently incorporated to predict peptide sequences with a high likelihood for HLA presentation. Investigation of the tumor-wide clonality and temporal stability of the candidates was performed on extensive RNA-seq data from our spatially mapped intratumoral samples and longitudinally collected tumor tissue RNA-seq. Proteomic validation was conducted through mass-spec analysis of the Clinical Proteomic Tumor Analysis Consortium (CPTAC)-GBM repository (n=99).

Results Our analysis of TCGA-GBM/LGG bulk RNA-seq identified 249 putative neojunctions that translate into 222 cancer-specific peptide sequences encoding 21,489 tumor-specific n-mers (8–11 amino acids in length, figure 1). Both prediction algorithms concurrently identified 271 n-mers likely to bind and be presented by HLA*A0101, HLA*A0201, HLA*A0301, HLA*A1101, or HLA*A2402. We confirmed the expression of 17 out of 74 HLA*A0201-binding candidates in RNA-seq of two HLA*A0201+ patient-derived glioma cell lines with a subset of candidates found tumor-wide (figure 2). Analysis of CPTAC-GBM mass-spec data detected 42 tumor-specific peptides generated specifically from 23 GBM-specific splicing events (figure 3). 4 candidates were selected for downstream immunogenicity analysis and were selected based on high in silico HLA-presentation scores and detection in RNA sequencing and mass spectrometry. In vitro sensitization of healthy donor-derived CD8+ T-cells was performed with the 4 candidates along with an influenza positive control condition and a no peptide negative control condition. 1 of the 4 neoantigen candidates, mutant-RPL22, was shown to elicit a CD8+ T-cell-specific immune response based on IFNγ ELISA assay analysis (figure 4).

Conclusions Tumor-specific neojunctions identified in our unique integrative pipeline present novel candidate immunotherapy targets for gliomas and offer a new avenue in neoantigen discovery across cancer types.


  1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van ‘t Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415–21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin]. PMID: 23945592; PMCID: PMC3776390.

  2. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; Cancer Genome Atlas Research Network, Rätsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 2018 Aug 13;34(2):211–224.e6. doi: 10.1016/j.ccell.2018.07.001. Epub 2018 Aug 2. PMID: 30078747.

  3. Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, Ganier O, Gilet J, Tosello J, Nemati F, Pierron G, Waterfall JJ, Barnhill R, Gardrat S, Piperno-Neumann S, Popova T, Masson V, Loew D, Mariani P, Cassoux N, Amigorena S, Rodrigues M, Alsafadi S, Stern MH, Lantz O. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021 Aug;11(8):1938–1951. doi: 10.1158/2159-8290.CD-20-0555. Epub 2021 Apr 2. Erratum in: Cancer Discov. 2022 Mar 1;12(3):872. PMID: 33811047.

Abstract 80 Figure 1

Identification of top HLA-presented neoantigensNeoantigen sequences were predicted from glioma-specific neojunctions identified from our novel in silico pipeline. 398 top-candidates were selected based on high HLA-presentation scores identified in two independent HLA-prediction algorithms.

Abstract 80 Figure 2

RNA-level validation of neojunctionsRNA-expression of neojunctions was validated by analyzing RNA-sequencing data from two patient-derived HLA-A*0201 glioma cell lines. 74 of the 398 top candidates were shown to bind strongly to HLA-A*0201. Neojunctions expressing 14 of the candidates were detected in either cell lines

Abstract 80 Figure 3

Peptide-level validation of NJ-derived neoantigensProtein-level expression of the neojunctions was detected by analyzing mass-spectrometry data from CPTAC. Mass spectrometry data of GBM patients (n=99) detected 42 peptides that are uniquely derived from 23 unique neojunctions

Abstract 80 Figure 4

NJ-derived neoantigens elicit CD8+ T-cell responseFour neojunction-derived neoantigen candidates demonstrated high HLA-presentation scores and were detected on both an RNA- and peptide-level. Neoantigen sensitization was performed on donor derived PBMCs, and neojunction-derived mutant-RPL22 elicited a CD8+ T-cell-specific immune response

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.